Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BGB-43395 by BeiGene for Solid Tumor: Likelihood of Approval
BGB-43395 is under clinical development by BeiGene and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
BGB-43395 by BeiGene for Non-Small Cell Lung Cancer: Likelihood of Approval
BGB-43395 is under clinical development by BeiGene and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...
BGB-43395 by BeiGene for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
BGB-43395 is under clinical development by BeiGene and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Negative...